The recently signed Memoranda of Understanding with researchers from Ryerson University and the University of Ottawa will contribute towards building a better knowledge base surrounding medical marijuana in
The patent relates to Collegium’s Oxycodone DETERx formulation and contains claims that cover the Company’s lead product, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx technology. Collegium
Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. Defibrotide is a novel product
Testosterone Gel (1%) offers once-daily dosing, 24-hour coverage and three configurations: unit-dose tubes and packets and metered-dose pumps. Vogelxo and Testosterone Gel are a prescription medicine that contains
The patent will be in effect at least until May 2031. This patent covers the technology used in Eye-D®, the company’s controlled-release latanoprost insert currently in a Phase
ELELYSO is the first prescription medication to be certified kosher by the OU, a milestone for the brand which was approved by the U.S. Food and Drug Administration
NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena’s lead development agent in multiple ongoing and planned clinical trials. Once issued, the patent
Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea. Cortex previously conducted a 21 day,
The combination creates one of the world’s fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015. In conjunction with the close of
In the study a statistically significant greater proportion of rifaximin treated subjects (as compared to placebo) responded to repeat treatment as assessed by the composite primary endpoint of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.